evoke interest in the reader about the article. This is because a reader first looks at the title of an article and then decides whether to read the abstract or not and if the abstract is interesting then decides if he/she should read the full text.
In my estimation, the original articles are the least read and this is not because the majority of readers are not interested in studies, but because they find the language of science a barrier. It is with this intent that, since the last two years, we have been preparing a short summary cum comment on original articles and printing it within the table of contents itself.
It is heartening for me to note that the most frequent error found in our titles was that of minimization. I must admit that this was purposeful with the intent of making the titles more reader friendly. Majority of readers are more interested in the message from the article rather than the study design. While the study design is extremely important to the expert reader with special interest in the subject, it can always be mentioned in the abstract. The old recommendation of mentioning the study design and study subjects in titles was based on the need of old search engines to look for appropriate articles for researchers. Today's search engines can find words not just in titles and abstracts but anywhere within the full text. In such a scenario even mentioning key words for articles is fast becoming redundant.
Finally, in this study, the error definitions used by the authors are made by the authors themselves and have not been subjected to any form of validation. Even authors agree that there are no guidelines made by the International Council of Medical Journal Editors. In such a situation it is difficult to comment further on the specifics of the above study. The bottom line is that it is difficult to make a straight jacket for all titles and if one tries to do, such long winding titles will start sounding similar, monotonous and imposing for the average reader. More importantly, message of an article may get lost in such titles.
I thank the Dr. Singh and colleagues for focusing attention onto the important subject of choosing a title, and I hope that in future, they point their attention to more substantial parts of articles like statistical analysis or methodology or abstracts or method of presentation of tables or figures in articles. This will serve well the purpose of science and more specifically, have more useful carry home messages for our readers, authors and editors.
Uday Khopkar Uday Khopkar

Editor
Langerhans cell histiocytosis Langerhans cell histiocytosis presenting with hypopigmented presenting with hypopigmented macules macules Sir, A 3-year-old boy was referred to us by the oncology department for hypopigmented skin lesions, mainly over the upper back. The patient was being evaluated in the oncology department under the provisional diagnosis of Langerhans cell histiocytosis. The patient had presented to the oncology department with progressive proptosis associated with polyuria and polydipsia of 6 months' duration. The hypopigmented skin lesions had been recurring since the age of 4 months, and the parents mentioned that the common sites affected were the face and the upper back. Skin lesions were asymptomatic. There was no history of any erythematous, vesicular, nodular, or ulcerative lesions. The patient had mild scaling of the scalp but no significant crusting or oozing at any stage. There was no history of any other significant skin or mucosal lesions. The patient had been on topical emollients for the skin lesions, and there was no definite history of topical steroids. The patient's mother mentioned that the child had recurrent episodes of fever and upper respiratory tract infections, but had no significant weight loss or weakness. At the time of presentation, the patient did not have any significant respiratory or neurological symptoms. The child did not have a history of any spontaneous fractures or bone pains.
On dermatological examination, the patient was found to have lesions mainly over the upper back and forehead, with scattered lesions over the front of his chest and neck. The majority of the lesions were hypopigmented macules with a few scattered skin-colored papules [ Figure 1 ]. There was mild scaling of the scalp but no significant involvement of the axilla or other body flexures. No evident purpuric, vesicular, pustular, nodular, or ulcerative lesions were seen. Mucosae and nails were normal. Langerhans cell histiocytosis (LCH) was the first possible clinical diagnosis considering the presence of proptosis, diabetes insipidus, and skin lesions. However, the nature of the skin lesions was not typical enough to suggest the possibility of cutaneous lesions of LCH; because though the lesions were mainly over the seborrheic sites with a few papular lesions, the majority of the lesions were hypopigmented macules.
A skin biopsy taken from the hypopigmented macules revealed focal basal cell degeneration, exocytosis, and spongiosis. Papillary dermis showed infiltrate of histiocytes with folded nuclei, fine chromatin, and inconspicuous nucleoli admixed with lymphocytes and a few eosinophils. No significant mitosis was seen, and adnexal structures appeared unremarkable [ Figure 2 ]. Immunohistochemistry showed S-100 positivity in the histiocytic cells. The histopathology findings were consistent with the diagnosis of LCH. The one major limitation in our case was the lack of confirmation of LCH with CD1a or electron microscopy. However, we sincerely feel that the histopathological findings along with S-100 positivity, along with the typical clinical features like proptosis, diabetes insipidus, and the radiological changes, warrant a diagnosis of LCH.
Other significant investigations included a bone marrow aspiration and biopsy, which revealed a normocellular Based on the results of investigation, the patient was started on chemotherapy for multi-system LCH with vinblastine and prednisolone and is since under regular follow-up and treatment by the oncology department. For the skin lesions, the patient was put on topical emollients and mild steroids, with good improvement. No new skin lesions have developed since the patient was started on chemotherapy; however, the hypopigmentation has not completely subsided.
Skin involvement is common with Langerhans cell histiocytosis (LCH), and up to 50% of cases with multi-system disease may initially present with a rash, the intertriginous zones and lumbosacral areas being the most commonly affected. [1] The common skin lesions described as part of LCH include vesiculopustules, seborrheic dermatitis-like rash, mucosal lesions (erosions, petechiae, and granulomas), erythematous papules, nodular ulcerative lesions, and generalized petechiae. [2, 3] Skin lesions in varicelliform pattern, with umbilicated vesicular lesions, have also been described. [4] Hypopigmented lesions have been described commonly in LCH as a sequelae following healing of papular or nodular lesions, especially in the context of congenital self-healing Langerhans cell histiocytosis (CSHLCH); [5] but to the best of our knowledge, hypopigmented macules histopathologically showing features of active LCH have not been described in multi-system disease.
Lafora's disease diagnosed on Lafora's disease diagnosed on axillary skin biopsy in 3 patients axillary skin biopsy in 3 patients Sir, Lafora's disease is a rare neurometabolic disorder resulting in progressive decline in mental function. It is one of the five major conditions which produce progressive myoclonus epilepsy. [1, 2] It is characterized by pathognomonic endoplasmic reticulum-associated polyglucosan accumulations. [3] The syndrome of classic Lafora's disease was first described by Unverricht in 1891. [2] The disease usually commences between the ages of 11 and 18 years, with equal incidence in both the sexes. [1] The most common presenting feature is a single seizure followed by progressive myoclonus, generalized seizures, intellectual decline, and severe motor and coordination impairments. [4] Death usually occurs within 10 years, most commonly due to pneumonia or complications related to degeneration of the nervous system. [1] The diagnosis of Lafora's disease is based on demonstration of intracytoplasmic inclusions called Lafora bodies. [2, 5] We have come across 3 cases of Lafora's disease in which Lafora bodies were demonstrated in the axillary skin biopsy, which is the best diagnostic procedure according to our experience.
Three male patients in their second decade (16, 17, and 16 years) presented with a history of generalized convulsions, which started in the 10 th , 12 th , and 14 th years respectively. The clinical features were almost similar in all the 3 cases. There was progressive development of weakness, incoordinated movements, and decrease in school performance. Impairment of recent and remote memory, registration, recall, attentiveness, and intelligence with progressive mental deterioration and total disability was noted. There was no nocturnal myoclonus. Upon reevaluation, similar family history was obtained in that the elder sisters in the first 2 patients, had died of a similar illness. The third patient did not give history of any affected sibling.
On general physical examination, in the first case the boy was stuporous, dehydrated, and had bed sores. The other 2 cases did not reveal any significant abnormalities. Systemic examination was normal. No focal neurologic deficits were found. Reflexes were normal.
On investigations, hematological parameters, biochemical parameters, and urine analysis were all within normal limits. Examination of cerebrospinal fluid was normal. X-ray of chest and skull showed no abnormalities. Electroencephalogram (EEG) showed bilateral diffuse low voltage, delta waves slowing with frequent generalized, multifocal spike discharges. Histopathological examination of the hematoxylin and eosin-stained sections of the skin biopsy taken from the axillary region demonstrated no discernible histopathological abnormalities. Periodic acid Schiff stain (PAS), with diastase, revealed presence of Lafora bodies which were round-to-oval intracytoplasmic PASpositive, diastase-resistant inclusions within the acinar cells of apocrine [ Figure 1 ] and eccrine glands.
The Lafora body inclusions in Lafora's disease are found in neurons, liver, skin, bone, and muscle. In 1981, Carpenter and Karpati proposed skin biopsy as a convenient method of diagnosing Lafora's disease by identifying Lafora bodies within eccrine ducts. Other authors have confirmed these findings. Lafora bodies have been noted in apocrine duct cells, dermal peripheral nerve bundles, and peripheral nerve inclusions in muscle biopsy specimens. [2] They are seen as concentric target-like laminations, 1 to 30 microns in diameter. They are PAS positive, diastase resistant, Alcian
